MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2017 International Congress

    Piperine potentiate the neuroprotective effect of quercetin against MPTP induced neurotoxicity in rats

    S. Singh, P. Kumar (Moga, India)

    Objective: (1) Quercetin is well tolerated bioflavonoid used as supplement for various disorders but problem is its low oral bioavailability and (2) Piperine is combined…
  • 2017 International Congress

    Protective effect of Myristicin against neurodegeneration in a 6-hydroxydopamine induced model of Parkinson’s disease in rats

    A. Morad Ganjeh (Karaj, Islamic Republic of Iran)

    Objective: This study examined the effect of pretreatment with Myristicin on the severity of 6-hydroxydopamine-induced Parkinsonism in Wistar rats in order to find out whether…
  • 2017 International Congress

    Piper betle L. Attenuates 6-OHDA Induced Apoptosis in SH-SY5Y Cells and Neuronal Injury in Caenorhabditis elegans Parkinson’s Model

    G. Shanmugam, A. Mohankumar, P. Sundararaj (Coimbatore, India)

    Objective: To explore the anti-apoptotic effects of Piper bitle leaf extract (PLE) on 6-OHDA induced cellular injury in human neuroblastoma cell SH-SY5Y. To analyse the neuroprotective…
  • 2017 International Congress

    Role of Apocyanin in modulating glial cell functions and associated inflammatory response in Lipopolysaccharide induced Parkinson’s disease model.

    N. Sharma, B. Nehru (Chandigarh, India)

    Objective: To explore the effect of apocyanin on glia mediated inflammatory response and α-synuclein aggregation in single intranigral LPS induced PD model Background: Converging lines…
  • 2017 International Congress

    MANF protects dopamine neurons and locomotion defect from Neurotoxin/Human alpha-synuclein-induced progressive Parkinson’s disease models in C.elegans.

    Z. Zhang (Shanghai, China)

    Objective: To study whether Mesencephalic astrocyte-derived neurotrophic factor (MANF) has beneficial effects in parkinson disease and its intracellular mechanisms.  Background: The distinguishing feature of Parkinson’s…
  • 2017 International Congress

    Neuroprotective effects of antidepressant mirtazapine against dopaminergic neurodegeneration in cultured cells and in parkinsonian mice possibly by targeting astrocytes

    M. Asanuma, I. Miyazaki, R. Kikuoka, S. Murakami, N. Isooka, Y. Kitamura (Okayama, Japan)

    Objective: In this study, we examined neuroprotective effects of mirtazapine and involvement of astrocytes in the effects using primary cultured cells and parkinsonian mice. Background:…
  • 2016 International Congress

    Identification of Usp8 as a toxicity modifying deubiquitinase for α-synuclein

    Z. Alexopoulou, J. Lang, R. Perrett, H.T. Kim, A.L. Goldberg, O. Ansorge, T.A. Fulga, G.K. Tofaris (Oxford, United Kingdom)

    Objective: To study whether ubiquitination in Lewy bodies is directly relevant to α-synuclein turnover and Parkinson's pathogenesis. Background: In Parkinson's disease, misfolded α-synuclein accumulates, often…
  • 2016 International Congress

    Risk factors for premature withdraw from the LS-1 PD study

    J.Y. Fang, S. Luo, M. Huang, R.B. Dewey, R. Hauser, G. Chen (Nashville, TN, USA)

    Objective: To identify risk factors for premature withdrawal from a large, multi-center Parkinson's disease clinical trial of possible neuroprotection. Background: Premature withdrawal (PW) of subjects…
  • 2016 International Congress

    Counteracting PINK1/parkin deficiency by activating alternative mitophagic pathway: a potential therapeutic intervention for Parkinson’s disease

    B. Koentjoro, J.S. Park, C.M. Sue (Sydney, Australia)

    Objective: To identify a new therapeutic target for developing neuroprotective treatment in Parkinson's disease (PD) by improving mitochondrial function through restoration of mitochondrial quality control…
  • 2016 International Congress

    Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson’s disease subtype

    I. Huertas Fernandez, S. Jesus, J.A. Lojo, F.J. Garcia Gomez, M. Caceres Redondo, J.M. Oropesa Ruiz, F. Carrillo, L. Vargas Gonzalez, J.F. Martin Rodriguez, P. Gomez Garre, D. Garcia Solis, P. Mir (Sevilla, Spain)

    Objective: To investigate whether Parkinson's disease (PD) motor subtypes differ in their levels of uric acid (UA), and if these differences correlate with the degree…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • #23285 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley